↓ Skip to main content

Psychological, behavioral and social effects of disclosing Alzheimer’s disease biomarkers to research participants: a systematic review

Overview of attention for article published in Alzheimer's Research & Therapy, November 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#43 of 1,085)
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news
10 news outlets
twitter
24 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
39 Dimensions

Readers on

mendeley
124 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Psychological, behavioral and social effects of disclosing Alzheimer’s disease biomarkers to research participants: a systematic review
Published in
Alzheimer's Research & Therapy, November 2016
DOI 10.1186/s13195-016-0212-z
Pubmed ID
Authors

S. A. S. A. Bemelmans, K. Tromp, E. M. Bunnik, R. J. Milne, S. Badger, C. Brayne, M. H. Schermer, E. Richard

Abstract

Current Alzheimer's disease (AD) research initiatives focus on cognitively healthy individuals with biomarkers that are associated with the development of AD. It is unclear whether biomarker results should be returned to research participants and what the psychological, behavioral and social effects of disclosure are. This systematic review therefore examines the psychological, behavioral and social effects of disclosing genetic and nongenetic AD-related biomarkers to cognitively healthy research participants. We performed a systematic literature search in eight scientific databases. Three independent reviewers screened the identified records and selected relevant articles. Results extracted from the included articles were aggregated and presented per effect group. Fourteen studies met the inclusion criteria and were included in the data synthesis. None of the identified studies examined the effects of disclosing nongenetic biomarkers. All studies but one concerned the disclosure of APOE genotype and were conducted in the USA. Study populations consisted largely of cognitively healthy first-degree relatives of AD patients. In this group, disclosure of an increased risk was not associated with anxiety, depression or changes in perceived risk in relation to family history. Disclosure of an increased risk did lead to an increase in specific test-related distress levels, health-related behavior changes and long-term care insurance uptake and possibly diminished memory functioning. In cognitively healthy research participants with a first-degree relative with AD, disclosure of APOE ε4-positivity does not lead to elevated anxiety and depression levels, but does increase test-related distress and results in behavior changes concerning insurance and health. We did not find studies reporting the effects of disclosing nongenetic biomarkers and only one study included people without a family history of AD. Empirical studies on the effects of disclosing nongenetic biomarkers and of disclosure to persons without a family history of AD are urgently needed. PROSPERO international prospective register for systematic reviews CRD42016035388 . Registered 19 February 2016.

Twitter Demographics

The data shown below were collected from the profiles of 24 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 124 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 124 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 20 16%
Researcher 18 15%
Student > Master 17 14%
Student > Bachelor 14 11%
Other 10 8%
Other 23 19%
Unknown 22 18%
Readers by discipline Count As %
Psychology 21 17%
Medicine and Dentistry 16 13%
Neuroscience 12 10%
Nursing and Health Professions 11 9%
Social Sciences 7 6%
Other 26 21%
Unknown 31 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 95. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 October 2018.
All research outputs
#328,001
of 21,069,566 outputs
Outputs from Alzheimer's Research & Therapy
#43
of 1,085 outputs
Outputs of similar age
#8,259
of 310,459 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#5
of 58 outputs
Altmetric has tracked 21,069,566 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,085 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.2. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,459 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 58 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.